Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000779361 | SCV001581199 | pathogenic | Glutamate formiminotransferase deficiency | 2021-09-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000779361 | SCV002802956 | pathogenic | Glutamate formiminotransferase deficiency | 2021-11-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002535653 | SCV003711842 | pathogenic | Inborn genetic diseases | 2022-01-31 | criteria provided, single submitter | clinical testing | The c.763C>T (p.R255*) alteration, located in exon 6 (coding exon 6) of the FTCD gene, consists of a C to T substitution at nucleotide position 763. This changes the amino acid from an arginine (R) to a stop codon at amino acid position 255. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from gnomAD, the T allele has an overall frequency of <0.01% (4/281380) total alleles studied. This mutation has been identified in a few individuals with glutamate formiminotransferase deficiency in conjunction with an FTCD frameshift variant (Majumdar, 2017; Ahrens-Nicklas, 2019). Based on the available evidence, this alteration is classified as pathogenic. |
OMIM | RCV000779361 | SCV001370722 | pathogenic | Glutamate formiminotransferase deficiency | 2022-06-17 | no assertion criteria provided | literature only |